The Mayo Clinic nuclear medicine therapy team is among the most experienced in creating radioactive drugs and using and administering them safely. Nuclear medicine experts are experienced in:
- Preparing you for radioactive tracers
- Computer processing and image enhancement
- Radioactive chemical compound preparation and administration
- Radioactive therapy
- Radiation safety
Mayo Clinic doctors also have extensive experience treating people with carcinoid tumors, neuroendocrine tumors, prostate cancer and every other condition for which nuclear medicine therapy might be a treatment option. For example, each year they care for more than 1,900 people with neuroendocrine tumors, including rare types. People with uncommon or complex conditions who are seen at medical institutions that treat many people with such conditions seem to have better outcomes than those seen at institutions that treat these conditions less frequently.
Nationally recognized expertise
Mayo Clinic Cancer Center meets strict standards for a National Cancer Institute comprehensive cancer center, which recognizes scientific excellence and a multidisciplinary approach to cancer prevention, diagnosis and treatment.
Mayo Clinic in Rochester, Minn., Mayo Clinic in Phoenix/Scottsdale, Ariz., and Mayo Clinic in Jacksonville, Fla., are ranked among the Best Hospitals for cancer by U.S. News & World Report.
Aug. 25, 2020
- Johnson GB (expert opinion). Mayo Clinic. March 9, 2020.
- Kendi AT (expert opinion). Mayo Clinic. May 29, 2019.
- Office of Patient Education. Peptide receptor radionuclide therapy (PRRT) for somatostatin-positive tumors. Mayo Clinic; 2018.
- Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine 2017; doi:10.1056/NEJMoa1607427.
- U.S. Food and Drug Administration (news release). FDA approves new treatment for certain digestive tract cancers. Jan. 26, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm. Accessed May 24, 2018.
- National Cancer Institute (news release). FDA approves new treatment for certain neuroendocrine tumors. Feb. 8, 2018. https://www.cancer.gov/news-events/cancer-currents-blog/2018/lutathera-fda-gastrointestinal-nets. Accessed May 24, 2018.
- Warner KJ. Allscripts EPSi. Mayo Clinic. April 29, 2019.
- Kendi AT, et al. Therapy with 177Lu-DOTATE: Clinical implementation and impact on care of patients with neuroendocrine tumors. American Journal of Roentgenology. 2019; doi:10.2214/AJR.19.21123.
- Halfdanarson, TR (expert opinion). Mayo Clinic. March 11, 2020.